Re: Isotype Controls
Bruce Davis, MD - Clinical Pathology (bdavis@beaumont.edu)
Fri, 29 Mar 1996 17:15:18 -0500 (EST)
Although this response should really come from Greg Stelzer, as chair of
the standardization and procedure validation sucommittee of the U.S. FCM
concensus conf for leukemia and lymphoma, I relay the thoughts regarding
isotypes in hematolymphoid malignancies. Yes, we feel isotype controls
per say as a separate tube is unnecessary for at least 2 reasons. 1)
these are not "normal cells" so CLIA regs for reference ranges are
irrelavent and 2) such studies should contain sufficient numbers of
antibodies that negative markers can substitute for "isotype controls"
(eg. in a B cell leukemia - CD4, CD8, CD3, CD7, etc. can function as
functional negative controls). On a personal note, I have been following
this practice for over two years and over 1000 leukemias and lymphomas
later and have not had a problem (to my knowledge).
Bruce H. Davis, M.D.
Director of Analytical Cytometry
Dept. of Clinical Pathology
William Beaumont Hospital
3601 W. 13 Mile Rd.
Royal Oak, Michigan 48073-6769
810-551-5137
FAX 810-551-8057
CD ROM Vol 2 was produced by staff at the Purdue University Cytometry Laboratories
and distributed free of charge as an educational service to the cytometry community.
If you have any comments please direct them to Dr. J. Paul Robinson, Professor & Director, PUCL,
Purdue University, West Lafayette, IN 47907. Phone:(317) 494-0757; FAX (317) 494-0517; Web http://www.cyto.purdue.edu
EMAIL robinson@flowcyt.cyto.purdue.edu
